Schizophrenia
Conditions
Interventions
D-cycloserine 25mgX2/day
placebo
Sponsors
Tokyo Medical and Dental University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects are all inpatients who fulfilled the following inclusion criteria: 1)DSM-IV (American Psychiatric Association 1994) diagnosis of schizophrenia; 2) 20-70 years old; 3) men and women; 4) outpatients and inpatients; 5) written informed consent is obtained from patients themselves after the description and explanations of the study to them orally and in writing.
Exclusion criteria
Exclusion criteria: Patients who meet the following criteria should be excluded: 1) under being treated with the structured psychotherapies or cognitive-behavioral therapies within 12 weeks before the beginning of this study; 2) DSM-IV diagnosis of substance-related disorders within 24 weeks before the beginning of this study; 3) under being treated with the electroconvulsive therapy within 12 weeks before the beginning of this study; 4) during pregnancy and lactation or the possible pregnancy within 30 days after the end of this study; 5) suicide attempt within 24 weeks before the beginning of this study; 6) history or complication of convulsive disorders; 7) history of hypersensitivity to D-cycloserine or lactose; 8) complication of serious organic brain diseases; 9) complication of serious somatic disorders including hepatopathy, nephropathy, cardiopathy, etc.; 10) implantation of metal materials in the body; 11) insertion of a cardiac pacemaker; 12) under being treated with D-cycloserine; 13) other conditions that are considered to be inappropriate to the present trial by its investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) PANSS (Scores of positive, negative, and total symptoms) 2) SANS (Scores of negative symptoms) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) PANSS (Scores of the individual subgroups of positive symptoms) 2) PANSS (Scores of the individual subgroups of negative symptoms) 3) SANS (Scores of the individual subgroups of negative symptoms) 4) GAS (Scores of the Global Assessment Scale) 5) HAM-D (Scores of the Hamilton Rating Scale for Depression) 6) DIEPSS (Scores of the Drug-Induced Extra-Pyramidal Symptoms Scale) 7) AIMS (Scores of the Abnormal Involuntary Movement Scale) 8) EQS (Scores of the Emotional Intelligence Scale) 9) The serum levels of D-cycloserine 10) The serum levels of D-serine 11) Brain MRI | — |
Countries
Japan
Contacts
Public ContactToru Nishikawa
Tokyo Medical and Dental University Graduate School Department of Psychiatry and Behavioral Sciences
Outcome results
None listed